References
- 1. A. H. N. Kamdje, P. F. S. Etet, L. Vecchio, J. M. Muller, M. Krampera and K. E. Lukong, Signaling pathways in breast cancer: Therapeutic targeting of the microenvironment, Cell. Signal.26 (2014) 2843–2856; https://doi.org/10.1016/j.cellsig.2014.07.03410.1016/j.cellsig.2014.07.03425093804
- 2. K. Velaei, N. Samadi, B. Barazvan and J. S. Rad, Tumor microenvironment-mediated chemoresistance in breast cancer, The Breast30 (2016) 92–100; https://doi.org/10.1016/j.breast.2016.09.00210.1016/j.breast.2016.09.00227668856
- 3. Q. J. Guo, J. Li and H. S. Lin, Effect and molecular mechanisms of traditional chinese medicine on regulating tumor immunosuppressive microenvironment, BioMed Res. Int.2015 (2015) 261620; https://doi.org/10.1155/2015/26162010.1155/2015/261620448674226161392
- 4. M. Pesic and F. R. Greten, Inflammation and cancer: tissue regeneration gone awry, Curr. Opin. Cell. Biol.43 (2016) 55–61; https://doi.org/10.1016/j.ceb.2016.07.01010.1016/j.ceb.2016.07.01027521599
- 5. M. Suarez-Carmona, J. Lesage, D. Cataldo and C. Gilles, EMT and inflammation: inseparable actors of cancer progression, Mol. Oncol.11 (2017) 805–823; https://doi.org/10.1002/1878-0261.1209510.1002/1878-0261.12095549649128599100
- 6. X. Y. Li, L. Su, Y. M. Jiang, W. B. Gao, C. W. Xu, C. Q. Zeng, J. Song, Y. Xu, W. C. Weng and W. B. Liang, The antitumor effect of xihuang pill on treg cells decreased in tumor microenvironment of 4T1 breast tumor-bearing mice by PI3K/AKT~AP-1 signaling pathway, Evid.-Based Compl. Alt. Med.2018 (2018) 6714829; https://doi.org/10.1155/2018/671482910.1155/2018/6714829593758029849718
- 7. F. R. Balkwill and A. Mantovani, Cancer-related inflammation: Common themes and therapeutic opportunities, Semin. Cancer Biol.22 (2012) 33–40; https://doi.org/10.1016/j.semcancer.2011.12.00510.1016/j.semcancer.2011.12.00522210179
- 8. Z. T. Li, Y. J. Zhu, C. C. Li, R. Trinh, X. Y. Ren, F. M. Sun, Y. F. Wang, P. Z. Shang, T. Wang, M. Wang, S. L. Morrison and J. Zhang, Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer, Oncoimmunology6 (2017) e1290038; https://doi.org/10.1080/2162402X.2017.129003810.1080/2162402X.2017.1290038538437628405526
- 9. F. L. Bai, Z. S. Niu, H. Tian, S. M. Li, Z. Lv, T. Y. Zhang, G. P. Ren and D. S. Li, Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy, Immunol. Lett.159 (2014) 36–46; https://doi.org/10.1016/j.imlet.2014.02.00910.1016/j.imlet.2014.02.00924613899
- 10. T. van der Heijden, I. Bot and J. Kuiper, The IL-12 cytokine family in cardiovascular diseases, Cytokine122 (2019) 154188; https://doi.org/10.1016/j.cyto.2017.10.01010.1016/j.cyto.2017.10.01029074035
- 11. K. Singh, M. Roy, P. Prajapati, A. Lipatova, L. Sripada, D. Gohel, A. Singh, M. Mane, M. M. Godbole, P. M. Chumakov and R. Singh, NLRX1 regulates TNF-α-induced mitochondria-lysosomal crosstalk to maintain the invasive and metastatic potential of breast cancer cells, BBA-Mol. Basis Dis.1865 (2019) 1460–1476; https://doi.org/10.1016/j.bbadis.2019.02.01810.1016/j.bbadis.2019.02.01830802640
- 12. K. A. Silverio and S. A. Patel, Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer (Review), Oncol. Lett.13 (2017) 2015–2020; https://doi.org/10.3892/ol.2017.572110.3892/ol.2017.5721540327428454356
- 13. S. Suman, P. K. Sharma, G. Rai, S. Mishra, D. Arora, P. Gupta and Y. Shukla, Current perspectives of molecular pathways involved in chronic inflammation-mediated breast cancer, Biochem. Bioph. Res. Commun.472 (2016) 401–409; https://doi.org/10.1016/j.bbrc.2015.10.13310.1016/j.bbrc.2015.10.13326522220
- 14. I. Uehara and N. Tanaka, Role of p53 in the regulation of the inflammatory tumor microenvironment and tumor suppression, Cancers10 (2018) 219; https://doi.org/10.3390/cancers1007021910.3390/cancers10070219607129129954119
- 15. J. F. Lima, S. Nofech-Mozes, J. Bayani and J. M. S. Bartlett, EMT in breast carcinoma – A review, J. Clin. Med.5 (2016) 65; https://doi.org/10.3390/jcm507006510.3390/jcm5070065496199627429011
- 16. L. Yan, F. Xu and C. L. Dai, Relationship between epithelial-to-mesenchymal transition and the inflammatory microenvironment of hepatocellular carcinoma, J. Exp. Clin. Cancer Res.37 (2018) 203; https://doi.org/10.1186/s13046-018-0887-z10.1186/s13046-018-0887-z611447730157906
- 17. L. EL-Hajjar, N. Jalaleddine, A. Shaito, K. Zibara, J. M. Kazan, J. El-Saghir and M. El-Sabban, Bevacizumab induces inflammation in MDA-MB-231 breast cancer cell line and in a mouse model, Cell. Signal.53 (2019) 400–412; https://doi.org/10.1016/j.cellsig.2018.11.00710.1016/j.cellsig.2018.11.00730445167
- 18. H. N. Chang, S. T. Huang, Y. C. Yeh, H. S. Wang, T. H. Wang, Y. H. Wu and J. S. Pang, Indigo naturalis and its component tryptanthrin exert anti-angiogenic effect by arresting cell cycle and inhibiting Akt and FAK signaling in human vascular endothelial cells, J. Ethnopharmacol.174 (2015) 474–481; https://doi.org/10.1016/j.jep.2015.08.05010.1016/j.jep.2015.08.05026341616
- 19. S. L. Hsuan, S. C. Chang, S. Y. Wang, T. L. Liao, T. T. Jong, M. S. Chien, W. C. Lee, S. S. Chen and J. W. Liao, The cytotoxicity to leukemia cells and antiviral effects of isatis indigotica extracts on pseudorabies virus, J. Ethnopharmacol.123 (2009) 61–67; https://doi.org/10.1016/j.jep.2009.02.02810.1016/j.jep.2009.02.028712679319429341
- 20. Y. H. Liang, H. X. Hou, D. R. Li, J. Qin, L. Qiu and H. H. Wu, Studies on in vitro anticancer activity of tryptanthrin B, Chin. Tradit. Herbal Drugs31 (2000) 531–533; https://doi.org/10.3321/j.issn:0253-2670.2000.07.029
- 21. J. P. Li, G. H. Zhu, Y. Yuan and M. X. Liu, Anti-tumor and immune function regulation effects of radix isatidis polysaccharides in vivo, Nat. Prod. Res. Dev.29 (2017) 2010–2016; https://doi.org/10.16333/j.1001-6880.2017.12.003
- 22. L. L. Liu, J. Chen and Y. P. Shi, Advances in studies on antitumor of Chinese materia medica with heat-clearing and toxin-resolving functions, Chin. Tradit. Herbal Drugs43 (2012) 1203–1212; https://www.cqvip.com/qk/80172x/201211/42183551.html
- 23. G. Honda and M. Tabata, Isolation of antifungal principle tryptanthrin, from Strobilanthes Cusia O. Kuntze, Planta Med.36 (1979) 85–86; https://doi.org/10.1055/s-0028-109724510.1055/s-0028-1097245461559
- 24. R. Kaur, S. K. Manjal, R. K. Rawal and K. Kumar, Recent synthetic and medicinal perspectives of tryptanthrin, Bioorg. Med. Chem.25 (2017) 4533–4552; https://doi.org/10.1016/j.bmc.2017.07.00310.1016/j.bmc.2017.07.00328720329
- 25. E. H. Jung, J. Y. Jung, H. L. Ko, J. K. Kim, S. M. Park, D. H. Jung, C. A. Park, Y. W. Kim, S. K. Ku, I. J. Cho and S. C. Kim, Tryptanthrin prevents oxidative stress-mediated apoptosis through AMP-activated protein kinase-dependent p38 mitogen-activated protein kinase activation, Arch. Pharm. Res.40 (2017) 1071–1086; https://doi.org/10.1007/s12272-017-0947-510.1007/s12272-017-0947-5
- 26. S. Lee, D. C. Kim, H. Y. Baek, K. D. Lee, Y. C. Kim and H. Oh, Anti-neuroinflammatory effects of tryptanthrin from Polygonum tinctorium Lour. in lipopolysaccharide-stimulated BV2 microglial cells, Arch. Pharm. Res.41 (2018) 419–430; https://doi.org/10.1007/s12272-018-1020-810.1007/s12272-018-1020-8
- 27. S. T. Yu, J. W. Chern, T. M. Chen, Y. F. Chiu, H. T. Chen and Y. H. Chen, Cytotoxicity and reversal of multidrug resistance by tryptanthrin-derived indoloquinazolines, Acta Pharmacol. Sin.31 (2010) 259–264; https://doi.org/10.1038/aps.2009.19810.1038/aps.2009.198
- 28. Y. W. Kwon, S. Y. Cheon, S. Y. Park, J. Song and J. H. Lee, Tryptanthrin suppresses the activation of the LPS-treated BV2 microglial cell line via Nrf2/HO-1 antioxidant signaling, Front Cell Neurosci.11 (2017) 18; https://doi.org/10.3389/fncel.2017.0001810.3389/fncel.2017.00018
- 29. M. J. Micallef, K. Iwaki, T. Ishihara, S. Ushio, M. Aga, T. Kunikata, S. Koya-Miyata, T. Kimoto, M. Ikeda and M. Kurimoto, The natural plant product tryptanthrin ameliorates dextran sodium sulfate-induced colitis in mice, Int. Immunopharmacol.2 (2002) 565–578; https://doi.org/10.1016/S1567-5769(01)00206-510.1016/S1567-5769(01)00206-5
- 30. R. Kaur, S. K. Manjal, R. K. Rawal and K. Kumar, Recent Synthetic and Medicinal Perspectives of Tryptanthrin, Bioorg. Med. Chem.25 (2017) 4533–4552; https://doi.org/10.1016/j.bmc.2017.07.00310.1016/j.bmc.2017.07.003
- 31. W. Zhou, Q. F. Zeng, D. Lai, J. L. Cho, X. Y. Zhang and X. C. Shen, Effect of tryptanthrin on proliferation of human breast cancer MCF-7 cells via MAPK signaling pathway, Chin. Pharm. J.54 (2019) 693–698; https://doi.org/10.11669/cpj.2019.09.005
- 32. X. M. Liao and K. N. Leung, Tryptanthrin induces growth inhibition and neuronal differentiation in the human neuroblastoma LA-N-1 cells, Chem. Biol. Interact.203 (2013) 512–521; https://doi.org/10.1016/j.cbi.2013.03.00110.1016/j.cbi.2013.03.00123500671
- 33. S. Han, D. F. Li, C. M. Wu, X. R. Ma, R. G. Song and Y. Wang, Synthesis and characterization of indolo quinazoline derivatives, Chem. Reagents33 (2011) 883–886; https://doi.org/10.13822/j.cnki.hxsj.2011.10.011
- 34. J. H. Feng, D. L. Song, S. Y. Jiang, X. H. Yang, T. T. Ding, H. Zhang, J. M. Luo, J. Liao and Q. Yin, Quercetin restrains TGF-β1-induced epithelial–mesenchymal transition by inhibiting Twist1 and regulating E-cadherin expression, Biochem. Bioph. Res. Commun.498 (2018) 132–138; https://doi.org/10.1016/j.bbrc.2018.02.04410.1016/j.bbrc.2018.02.04429425820
- 35. M. Mizui, Natural and modified IL-2 for the treatment of cancer and autoimmune diseases, Clin. Immunol.206 (2019) 63–70; https://doi.org/10.1016/j.clim.2018.11.00210.1016/j.clim.2018.11.00230415086
- 36. A. Tang and F. Harding, The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer, Cytokine: X1 (2019) 100001; https://doi.org/10.1016/j.cytox.2018.10000110.1016/j.cytox.2018.100001
- 37. X. G. Li, P. Lu, B. Li, W. F. Zhang, R. Yang, Y. Chu and K. Y. Luo, Interleukin 2 and interleukin 10 function synergistically to promote CD8+ T cell cytotoxicity, which is suppressed by regulatory T cells in breast cancer, Int. J. Biochem. Cell Biol.87 (2017) 1–7; https://doi.org/doi:10.1016/j.biocel.2017.03.00310.1016/j.biocel.2017.03.003718553428274688
- 38. M. H. Mannino, Z. W. Zhu, H. P. Xiao, Q. Bai, M. R. Wakefield and Y. J. Fang, The paradoxical role of IL-10 in immunity and cancer, Cancer Lett.367 (2015) 103–107; https://doi.org/10.1016/j.canlet.2015.07.00910.1016/j.canlet.2015.07.00926188281
- 39. R. Liu, H. G. Zheng, W. D. Li, Q. J. Guo, S. L. He, Y. Hirasaki, W. Hou, B. J. Hua, C. H. Li, Y. J. Bao, Y. B. Gao, X. Qi, Y. X. Pei and Y. Zhang, Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory micro-environment in Lewis lung carcinoma xenograft mouse model, J. Transl. Med.13 (2015) 366; https://doi.org/10.1186/s12967-015-0728-110.1186/s12967-015-0728-1465618426597177
- 40. D. Capece, D. Verzella, A. Tessitore, E. Alesse, C. Capalbo and F. Zazzeroni, Cancer secretome and inflammation: The bright and the dark sides of NF-κB, Semin. Cell Dev. Bio.78 (2018) 51–61; https://doi.org/10.1016/j.semcdb.2017.08.00410.1016/j.semcdb.2017.08.00428779979
- 41. M. Patel, P. G. Horgan, D. C. McMillan and J. Edwards, NF-κB pathways in the development and progression of colorectal cancer, Transl. Res.197 (2018) 43–56; https://doi.org/10.1016/j.trsl.2018.02.00210.1016/j.trsl.2018.02.00229550444
- 42. M. Egue, F. H. R. Gnangnon, M. T. Akele-Akpo and D. M. Parkin, Cancer incidence in Cotonou (Benin), 2014–2016 First results from the cancer Registry of Cotonou, Cancer Epidemiol.59 (2019) 46–50; https://doi.org/10.1016/j.canep.2019.01.00610.1016/j.canep.2019.01.00630685574
- 43. L. Su, Y. M. Jiang, Y. Xu, X. Y. Li, W. B. Gao, C. W. Xu, C. Q. Zeng, J. Song, W. C. Weng and W. B. Liang, Xihuang pill promotes apoptosis of Treg cells in the tumor microenvironment in 4T1 mouse breast cancer by upregulating MEKK1/SEK1/JNK1/AP-1 pathway, Biomed. Pharmacother.102 (2018) 1111–1119; https://doi.org/10.1016/j.biopha.2018.03.06310.1016/j.biopha.2018.03.06329710529